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The rat in biomedical research
The first drafts of the human genome were completed 
almost  a  decade  ago  [1,2].  Knowing  the  sequence, 
however, does not mean that we understand the code. To 
understand the function of the genome, the use of genetic 
model organisms is crucial. Traditionally, the mouse is 
the preferred mammalian genetic model organism owing 
to the relative ease by which its genome can be manipu­
lated. By contrast, the rat is more widely used in human 
physiology, pharmacology, neurobiology and toxicology 
studies [3]. Rats have also been extensively used to model 
complex  diseases,  including  cardiovascular  disease,  by 
selective breeding for naturally occurring disease pheno­
types [4]. One of the main advantages of using the rat for 
studying human biology is its relatively large size, which 
facilitates  experimental  and  surgical  interventions  [3], 
including in vivo imaging of neurons beneath the surface 
of  the  brain  in  a  freely  moving  rat  by  mounting  a 
miniature  two­photon  microscope  on  its  head  [5]. 
Further  more,  rats  are  often  preferred  over  mice  for 
neurobiological studies because of their cognitive abili­
ties.  For  example,  a  recent  study  showed  that 
neurogenesis and the maturation of newborn neurons in 
the adult hippocampus of rats are enhanced compared 
with the mouse brain [6]. Moreover, it was shown that 
these newborn neurons were more involved in response 
to  behavioral  activity  in  rats  compared  with  mice  [6]. 
These data suggest that the rat hippocampus may be a 
better model for that of the human.
Therefore, the desire to study the genetic elements that 
underlie  complex  traits  or  variation  in  physiological 
processes in the many established rat models has grown 
steadily in the past decade [7]. Unfortunately, our ability 
to manipulate the rat genome has lagged behind that of 
the  mouse,  with  its  seemingly  endless  possibilities  in 
reverse  genetics  and  standardized  mutant  phenotyping 
protocols [8,9] (Figure 1). However, the rat genetic tool­
box is developing rapidly as a result of several signifi  cant 
technological  advances,  including  the  optimization  of 
large­scale  random  mutagenesis  methods  and  the 
develop  ment  of  gene­targeting  approaches.  These  have 
enabled  the  generation  of  genetically  modified  rats, 
transforming the rat into a mature mammalian genetic 
model organism with many unique advantages.
The rat reference genome
A prerequisite for modeling human genetics in the rat is 
the  availability  of  a  high­quality  reference  genome 
sequence. The Brown Norway inbred strain was chosen as 
the strain to be sequenced because of its wide use in the 
research  community  as  a  control  or  reference  strain, 
mainly  in  physiological  studies.  The  first  draft  of  this 
reference  genome  was  largely  based  on  shotgun 
sequencing  and  was  released  in  2004  [10].  The  initial 
assembly covered about 90% of the estimated 2.75 Gbp rat 
genome  and  contained  a  similar  number  of  genes  as 
described for human and mouse (20,000­25,000). Since the 
first  genome  release,  the  rat  genomics  community  has 
driven  improvement  of  the  reference  sequence  by,  for 
example,  manual  curation  and  sequencing  of  bacterial 
artificial chromosome (BAC) clones, which is an ongoing 
process that will result in a more complete view of the rat 
genome  [7].  The  genome  sequence  of  the  spontaneous 
hyper  tensive rat was released this year and was found to 
contain  numerous  genetic  variants  compared  with  the 
Brown Norway reference genome, including hundreds of 
variants  resulting  in  dysfunctional  genes,  which  might 
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© 2010 BioMed Central Ltdcontribute  to  the  extensive  phenotypic  differences 
(including  those  relevant  to  common  human  disease) 
between these strains [11].
The  sequencing  of  at  least  ten  other  rat  strains  is 
under  way  [12,13].  The  development  of  the  massively 
parallel  sequencing  technologies  has  boosted  the 
feasibility of such projects and is already increasing the 
number  of  known  single  nucleotide  polymorphisms 
(SNPs) and copy number variants (CNVs) in commonly 
used rat strains.
Clearly,  the  availability  of  genome  sequences  of 
commonly  used  strains  provides  a  useful  resource  to 
investigate  the  potential  function  and  importance  of 
genomic  elements  and  polymorphisms  that  could  be 
associated with disease states. Both forward (phenotype­
driven)  and  reverse  (genotype­driven)  genetics 
approaches  are  instrumental  to  investigate  such  links 
between mutations and disease (see Figure 1).
Classical forward genetics in the rat
Forward  genetic  screens  are  excellent  tools  for 
dissecting the developmental and biochemical pathways 
that  under  lie  a  given  phenotype.  Naturally  occurring 
genetic varia  tions in selectively bred rat strains can be 
used to map phenotypic traits to the genome. Selective 
breeding and characterization has led to hundreds of rat 
strains  mimicking  complex  human  disease,  but  the 
causative genes of only a few disease models have been 
identified  by  positional  cloning  [7].  Identification  of 
causal  genetic  variants  has  been  facilitated  by  the 
development  of  detailed  SNP  panels  that  have  been 
used  to  genotype  more  than  300  inbred  strains  and 
hybrid  animals  [14].  Furthermore,  the  availability  of 
large  well­defined  recombinant  inbred  panels  enables 
quantitative  trait  loci  (QTL)  mapping  and  gene 
identification without the need for de novo genotyping. 
Other  available  specialized  mapping  panels  include 
consomic  strains,  inbred  strains  in  which  a  complete 
chromosome  is  replaced  by  a  homo  lo  gous  one  from 
another  strain  by  selective  breeding,  for  immediate 
mapping  of  traits  to  a  particular  chromosome,  and 
heterozygous stocks for fine mapping of QTLs to sub­
centimorgan intervals [7].
However, identifying causative polymorphisms under­
lying  disease  phenotypes  is  a  laborious  and  difficult 
process.  Because  the  number  of  genetic  elements 
involved  can  vary,  disease­gene  discovery  can  be 
extremely complex. Therefore, forward genetic screens 
in model systems often use the artificial introduction of 
indepen  dent genetic variations in the germline. Random 
muta  genesis approaches such as N­ethyl­N­nitrosourea 
(ENU)  mutagenesis  [15]  or  transposon­tagged  muta­
genesis [16] have been applied successfully in rats (see 
Figure 1). Hence, every mutant individual most probably 
carries  a  single  causative  genetic  change  that  can  be 
traced back to the genome using molecular biological 
techniques,  enabling  single  genes  involved  in  the 
phenotype of interest to be discovered.
Manipulating the rat genome using reverse genetic 
approaches
By contrast, genotype­driven approaches are based on 
mani  pulating  specific  genetic  elements  followed  by 
pheno  typic analysis. In general, the availability of com­
pletely sequenced genomes of a variety of organisms has 
increased  the  popularity  of  this  approach,  because 
know  ledge of the sequence is required. In the mouse, 
gene  knockout  technology  using  homologous 
recombination  combined  with  pluripotent  embryonic 
stem (ES) cells has been especially powerful [8], but until 
very recently, this technology was not available for the 
rat. Therefore, alter  native methods have been developed 
that  enable  efficient  generation  of  mutants  in  a  wide 
range of species. The application of these techniques to 
the  rat  has  resulted  in  the  generation  and 
characterization  of  a  growing  list  of  rat  knockout 
animals that model human disease (Table 1).
Figure 1. Genetic tools can be subdivided into two groups 
depending on the research question. Forward genetic approaches 
begin with a specified human disease phenotype. Animals 
displaying similar symptoms can be used to identify genetic 
elements underlying these disease traits by selective breeding and 
molecular biological techniques, such as linkage analyses. Both 
naturally occurring genetic variation and artificially induced variation 
can be used to score disease phenotypes. Alternatively, reverse 
genetic approaches are based on systematically mutating known 
genes to determine their role in human physiology and pathology 
by analyzing the phenotypic effects. ENU, N-ethyl-N-nitrosourea; 
ESC, embryonic stem cell; iPSC, induced pluripotent stem cell; HR, 
homologous recombination; ZFN, zinc-finger nuclease.
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The initial techniques that generated rat gene knockouts 
were  based  on  random  mutagenesis,  followed  by  the 
identification  of  mutations  in  genes  of  interest  and 
subsequent  phenotypic  assessment  of  the  mutant 
animals.  Numerous  models  have  been  generated  using 
ENU­based target­selected mutagenesis [17] (Figure 2a) 
and transposon­tagged mutagenesis [16,18] (Figure 2b). 
Although  these  techniques  can  efficiently  generate  rat 
mutants,  their  major  disadvantage  is  their  inability  to 
specifically target a particular gene of interest. Despite 
the  relative  technical  ease  of  applying  random  muta­
genesis  methods,  investigators  must  maintain  large 
animal repositories or archives and large investments are 
required  to  set  up  high­throughput  resequencing  to 
identify a mutant allele.
To knock out genes in a targeted fashion without the 
need  for  pluripotent  ES  cells,  one  can  use  genetically 
engineered  zinc­finger  nucleases  (ZFNs)  [19].  This 
approach is based on the observation that double­strand 
breaks (DSBs), which are potentially lethal to the cell when 
they  remain  unrepaired,  increase  either  homo  logous 
recombination and gene targeting or repair by error­prone 
nonhomologous  end  joining  (NHEJ)  [20].  By  fusing 
sequence­specific  zinc­fingers,  which  are  found  in  the 
DNA­binding  domains  of  most  transcription  factors  in 
most  eukaryotic  genomes  [19],  to  the  sequence­non­
specific  cleavage  domain  of  the  FokI  endonuclease, 
genomic DSBs in predetermined locations can be intro­
duced  (Figure  2c).  In  the  absence  of  a  homologous 
template  for  error­free  repair,  DSBs  will  be  repaired  by 
NHEJ,  which  is  often  accompanied  by  deletions  or 
insertions. If a DSB is introduced in the coding region of a 
gene or at an intron­exon boundary, repair by NHEJ can 
result in out­of­frame mutations or aberrant splicing and 
consequently  in  a  knockout  allele.  This  gene­targeting 
approach  has  been  successfully  applied  in  a  variety  of 
model organisms, including Drosophila melano  gaster [21], 
Arabidopsis  thaliana  [22],  zebrafish  [23,24]  and,  most 
recently, the rat [25]. The main challenges for successful 
ZFN­mediated  gene  targeting  are  the  design  of  the 
zinc­finger arrays to achieve sufficient specificity for the 
targeted gene and correct expression of the ZFNs to ensure 
germline transmission of the targeted gene (Box 1).
An  advantage  of  the  ZFN­mediated  gene­knockout 
technology  is  its  speed.  After  injecting  the  ZFNs  into 
embryos,  ZFN­modified  founders  can  be  scored  in  a 
matter of months. Furthermore, because ZFN­mediated 
DSBs  in  a  gene  of  choice  increases  the  efficiency  of 
homologous recombination in vivo [26], this technique 
could  enable  targeted  knock­in  animals,  by  simply  co­
injecting an artificially assembled construct together with 
the ZFNs. This would broaden the genetic toolbox in the 
rat  by  allowing  techniques  that  otherwise  depend  on 
culturing  and  manipulating  ES  cells  (for  example,  the 
generation  of  conditional  knockout  alleles  and  in  vivo 
cell­lineage  tracing),  making  targeted  mutagenesis  an 
indispensable genetic tool to model human disease.
However, designing, generating and testing constructs 
encoding specific ZFNs for generating a single mutant 
allele  is  relatively  laborious  and  time­consuming.  In 
addition, large numbers of fertilized oocytes have to be 
injected and many animals have to be generated to isolate 
knockout  alleles  for  a  single  gene  [25].  Therefore,  for 
large­scale  studies,  for  example  a  community  effort  to 
systematically generate knockout alleles for all rat genes, 
random  mutagenesis  techniques,  such  as  ENU  muta­
genesis or transposon­mediated mutagenesis, could still 
be the preferred option, as these techniques are typically 
highly efficient in generating large collections of mutant 
alleles using a limited number of animals.
Emerging genetic tools: propagating pluripotent 
rat cells
In the past two decades, ‘classical’ gene targeting based on 
homologous  recombination  in  pluripotent  ES  cells  has 
been  one  of  the  most  powerful  tools  in  genetics  [8]. 
Having such tools available for the rat has been a long­
lasting  quest  for  many  research  laboratories.  For 
successful gene targeting, it is crucial to maintain a cell 
type in vitro that is ultimately capable of contributing to 
the germline when placed back in a developing embryo. A 
Table 1. Characterized rat genetic knockout models
Knocked out gene  Technology   Involvement  Biological implication  References
Brca2  ENU mutagenesis  DNA repair  Tumorigenesis  [47,66]
Apc  ENU mutagenesis  Wnt signaling  Tumorigenesis  [48]
Msh6  ENU mutagenesis  DNA repair  Tumorigenesis  [49]
Il2rg  ZFN-mediated gene targeting  Immune response  Immunology  [60]
Sert  ENU mutagenesis  Emotion, motivation and cognition  Complex behavior   [67]
Pmch  ENU mutagenesis  Bodyweight regulation  Complex behavior  [68]
Mc4r  ENU mutagenesis  Bodyweight regulation  Complex behavior  [69]
ENU, N-ethyl-N-nitrosourea; ZFN, zinc-finger nuclease.
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Page 3 of 9gene of choice is targeted in vitro by offering these cells an 
artificially engineered piece of DNA, of which a part is 
homologous  to  the  target  sequence  and  required  for 
recombination,  and  a  part  is  non­homologous  that 
includes  selection  markers,  reporter  genes  and 
sequence­specific recombinase genes, for example (Figure 
2d).  Successful  gene  targeting  by  homologous 
recombination is heavily dependent on cell proliferation 
because colonies that derive from individual successfully 
recombined cells need to be selected for and expanded. 
Figure 2. Techniques for manipulating the rat genome. (a) The mutagenicity of N-ethyl-N-nitrosourea (ENU) is the result of the ability to 
transfer the ethyl group, shown highlighted in orange, to nucleotides in DNA. During replication this can result in the mis-insertion of a nucleotide 
and after another round of replication in a single base pair substitution. (b) Schematic overview of germline Sleeping Beauty (SB) transposition. 
A transgenic rat expressing the transposase gene is crossed with a transgenic rat that carries the transposon in its genome. This will produce 
double transgenic ‘seed rats’ with transposition events in their germ line, which can be fixed by outcrossing them with wild-type animals. Inverted 
terminal repeats (ITR) are shown as red triangles. (c) A DSB is introduced at a specific locus by fusing two zinc-finger (ZF) arrays to monomeric FokI 
domains. When no homologous template is available for repair by homologous recombination, the DSB is repaired by the error-prone mechanism 
of nonhomologous end joining (NHEJ). This can result in insertions or deletions and consequently out-of-frame mutations. (d) Schematic 
representation of gene targeting by homologous recombination. A DSB near a gene of interest (G) is repaired using exogenous DNA as template. 
Black lines indicate DNA sequence homologous to the target; red lines indicate nonhomologous DNA (*).
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reimplanted into their natural context. Currently, the only 
type of naturally occurring cell fulfilling these criteria is 
the  pluripotent  ES  cell,  which  is  a  relatively  rapidly 
dividing cell that can be placed back into blastocysts after 
gene  targeting.  Multipotent  spermato  gonial  stem  cells 
(SSCs) have been studied for the same purpose. Although 
these cells have been isolated successfully from rats and 
can  be  propagated  in  culture  and  contribute  to  the 
germline  when  placed  back  in  recipient  testes  [27,28], 
they expand relatively slowly and are probably unsuitable 
for  gene  targeting  by  homologous  recombination  and 
subsequent marker selection. There  fore, a prerequisite for 
gene targeting remains the availa  bility of pluripotent ES 
cells, but despite many efforts [29­31], these could not be 
isolated  and  cultured  for  the  rat.  However,  by  using  a 
specific culture medium contain  ing 3 or 2 differentiation 
inhibitors (3i or 2i medium), it was recently shown that 
true  pluripotent  rat  ES  cells  could  be  isolated  and 
propagated in vitro [32,33], which is the first, and arguably 
most  important,  step  necessary  for  ‘classical’  gene 
targeting in this species (Box 2). Very recently, the first 
example of gene targeting by homolo  gous recombination 
was demonstrated in such cells for the rat, resulting in the 
generation of a targeted p53 gene knockout [34].
Rat  induced  pluripotent  stem  cells  (iPS  cells)  have 
recently been generated [35,36]. This technique is based 
on ectopic expression of four defined genes: Oct-4, Sox2, 
c-myc  and  Klf4,  which  initiate  dedifferentiation  of 
somatic  cells,  for  example  fibroblasts,  to  a  pluripotent 
state  [37].  If  kept  under  the  right  culture  conditions, 
these cells retain their pluripotency. Importantly, it was 
shown that mouse iPS cells form viable chimeras and can 
contribute to the germline when injected into blastocysts 
[38,39]. It is conceivable that propagation of rat iPS cells 
under 3i or 2i conditions is essential to maintain pluri­
potency, similar to rat ES cells. Indeed, a study reported 
that rat iPS cells maintained under conditions standard 
for mouse ES cells did not yield chimeras when injected 
into  blastocysts  [36].  In  contrast,  chimaeras  were 
obtained when the rat iPS cells were maintained under 
slightly modified 3i conditions [35]. However, so far no 
germline  contribution  has  been  reported,  probably  for 
similar reasons to those that hinder efficient homologous 
recombination in ES cells (see Box 2).
It is difficult to predict when rat knockout production 
using  homologous  recombination  in  stem  cells  will 
become a commonly used technique. Although proof of 
principle exists [34], the method is still far from efficient. 
The  conditions  for  homologous  recombination  in 
Box 1. Gene targeting mediated by zinc-finger nucleases
Zinc-finger nucleases (ZFNs) are genetically engineered enzymes that cut DNA at predetermined sites. The unique features that make 
zinc-fingers ideal for directing enzymatic domains, such as the nuclease FokI, to predetermined genetic loci are that each finger binds its 
3-bp target site independently and that zinc-fingers have been identified for almost all of the 64 DNA triplets [54]. By fusing independent 
fingers, target-site specificity is achieved and should increase with the number of fingers used. In addition, to cut DNA, the FokI cleavage 
domain must dimerize, which is achieved by binding two sets of zinc-fingers, each linked to a monomeric cleavage domain, with binding 
sites in an inverted orientation and thereby enhancing site specificity [54].
There are different ways to generate zinc-finger nucleases (ZFNs); the most accessible method is modular assembly via standard 
recombinant DNA technology. Finding a suitable target site in the gene of interest is key to this approach. In particular, zinc-fingers that 
target 5’-GNN-3’ (where N is any base) triplets in the target sequence have been tested extensively and give the most encouraging results 
[54]. However, high failure rates have been reported for modularly assembled zinc-finger arrays, especially for target sites composed of 
two, one or no 5’-GNN-3’ triplets [55]. Although some successful targeting has been reported with modularly assembled ZFNs in human 
cells [56] and Drosophila melanogaster [57], inconsistencies in the success rate [58] have up to now made this method inefficient for routine 
gene targeting in model organisms.
Alternatively, zinc-finger arrays can successfully be constructed in an unbiased way by using a cell-based selection method, such as the 
publicly available oligomerized pool engineering (OPEN) technique [59]. However, cell-based selection methods are labor intensive and 
time consuming, and ZFNs made using OPEN are so far limited to targeting 5’-GNN-3’ repeats, which occur rarely in a given gene [58]. 
Finally, the company Sangamo Biosciences uses a proprietary method for designing ZFNs [24], which is licensed to Sigma-Aldrich. So far, 
this system is the only method that has successfully generated ZFN-modified knockout rats [25,60]; however, it is expensive. Custom-made 
ZFNs are sold for US$35,000 to researchers capable of injecting them on their own (see below). Alternatively, a knockout breeding pair can 
be bought for $95,000, with the company maintaining the intellectual property.
To establish germline transmission of an aberrantly repaired gene of interest, the ZFNs are injected into fertilized oocytes, which can 
give rise to chimeric genetically modified offspring [25,60]. Subsequently, these ZFN-modified founders are identified and crossed with 
wild-type animals to generate an F1 population carrying the modified allele in their genome. However, off-target effects of the ZFNs, 
such as cleavage and mutagenesis of genomic loci other than the target, should be taken into account because this increases toxicity 
and background mutations [21]. Nevertheless, short-term expression of the ZFN, by injecting mRNA instead of plasmid DNA, will most 
probably decrease these effects, without affecting the efficiency of the approach [25]. Furthermore, outcrossing to the parental strain 
should eliminate unwanted background mutations.
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optimal  strain  combinations  (donor  cells  and  recipient 
strains) need to be identified. Nevertheless, the isolation 
and generation of pluripotent rat ES cells and iPS cells are 
major steps forward in the field of rat genetics.
Remaining technical challenges
Creating archives of mutant alleles
Because  mutant  rat  lines  are  being  generated  using 
many  different  approaches,  ranging  from  random  to 
targeted  gene  mutagenesis  [40,41],  systematically 
archiving  the  mutant  lines  becomes  a  challenge. 
Clearly,  maintaining  large  living  repositories  of 
multiple  mutant  lines  is  expensive  and  extremely 
laborious.  Therefore,  much  effort  has  been  put  into 
optimizing protocols to archive frozen rat sperm that 
can  subsequently  be  revived  by  intracytoplasmic 
sperm injection (ICSI) [42]. Although this technique is 
commonly used for cryopreserving mouse lines, it is a 
challenge  to  revive  rat  sperm.  Indeed,  only  a  few 
laboratories are capable of reviving the mutant lines, 
which is a prerequisite for archiving large collec  tions 
of mutants.
The  isolation  and  propagation  of  pluripotent  rat  ES 
cells and multipotent spermatogonial stem cells (SSCs) 
offer an alternative to frozen archives of mutant alleles, 
without the need to generate large collections of living 
animals. Recently, in vitro mutagenesis of rat SSCs was 
reported  by  co­transfecting  a  transposon  plasmid 
contain  ing  a  gene­trap  selection  cassette  and  a  helper 
plasmid  encoding  a  hyperactive  Sleeping  Beauty  (SB) 
transposase  [43].  In  this  way,  gene­trap  events  can  be 
selected in culture and SSCs carrying mutations in a gene 
of interest can be revived, expanded in culture and placed 
back  in  recipient  males  for  germline  transmission. 
Theoretically, the stem cells could also be used for in vitro 
chemical  mutagenesis  to  generate  large  archives  of 
mutant alleles, which has also been done with mouse ES 
cells [44]. To knock out 95% of all the rat genes, a living 
library or sperm archive of around 40,000 rats has to be 
generated [45], which is currently probably not feasible. 
However, a large number of ES cells or iPS cells can easily 
be mutagenized in a Petri dish, clonally expanded and 
split for DNA isolation and cryopreservation. Large sets 
of  genes  of  interest  or  even  whole  exomes  of  these 
cryopreserved  clones  can  be  screened  using  next­
generation  sequencing  techniques,  combined  with 
genomic enrichment strategies [46].
Phenotyping rat mutants
Although  numerous  rat  knockout  models  have  been 
generated [40,41], the systematic characterization and 
application of these animals in modeling human disease 
is still underdeveloped. The lack of progress in systemic 
phenotypic screening protocols might be because of the 
emphasis on genomic manipulation and technological 
developments. Alternatively, researchers who tradition­
ally  work  with  rats  might  find  it  hard  to  apply  the 
genetic models in their analyses and prefer, for example, 
to manipulate the system pharmacologically. So far, the 
limited  phenotypic  analyses  of  rat  knockout  models 
have  been  based  on  specific  biological  processes  and 
have therefore been compared with similar phenotypes 
in  mouse  knockout  models.  Although  phenotypic 
similar  i  ties  are  useful  to  verify  gene  function,  many 
phenotypic differences have also been observed, adding 
important biological novelty and complementarities of 
the  rat  model  compared  with  the  mouse.  A  good 
example of this is the phenotypic analyses of rat models 
in which important tumor suppressor genes have been 
knocked  out  (for  example,  Brca2  [47],  Apc  [48]  and 
Msh6  [49]  (see  Table  1).  Although  mouse  knockout 
models  have  been  extremely  powerful  tools  for 
identifying important oncogenes and tumor suppressor 
genes,  there  are  discrepancies  between  the  human 
disease  phenotypes  and  those  observed  in  mouse 
models. Furthermore, mouse models that lack the same 
gene  but  in  a  different  strain  background  display 
important  differences,  empha  siz  ing  the  need  for 
comparable  mammalian  mutant  models  in  different 
species to enable in vivo phenotypic comparison and to 
filter  out  species­  or  strain­specific  effects.  Although 
the models listed in Table 1 do not perfectly mimic the 
associated  human  tumorigenesis,  clear  differences  are 
observed  in  tumor  spectra  and  tolerance  to  tumor 
development. In general, the rat displays a later onset of 
spontaneous  tumorigenesis,  increased  survival  and  a 
capacity  to  bearing  large  tumors  compared  with  the 
mouse [48,49].
However, to fully deploy the advantages of the rat as a 
mammalian genetic model organism, complementary to 
the mouse, more comprehensive, systematic phenotypic 
analyses  would  be  highly  beneficial.  Extensive  pheno­
typing  protocols  similar  to  those  developed  for  mice 
[50]  are  required  to  help  identify  new  and  important 
physiological  roles  of  gene  products,  and  to  unravel 
genetic  pathways.  Recent  initiatives  on  this  front 
include  the  Japanese  Rat  Phenome  Project,  which 
assayed a variety of parameters in dozens of strains [51], 
the  PhysGen  program,  which  characterized  multiple 
con  somic  strains  for  a  large  set  of  cardiovascular 
phenotypes,  and  the  EURATools  procedures  for 
systematic  charac  terization  of  heterogeneous  stock 
animals  [7].  The  need  to  centralize  and  standardize 
extensive phenotype protocols has long been recognized 
in the mouse [52] and the field of rat genetics may very 
well  learn  from  the  experiences  of  the  mouse 
community in the past decades.
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The  strength  of  the  rat  as  a  model  organism  is  the 
availability of a wealth of detailed physiological, pharma­
cological and neurobiological phenotypic know  ledge. To 
map  these  traits  to  elements  in  the  genome,  the 
community  was  prompted  to  expand  the  rat  genetic 
toolbox [3]. Significant progress has been made toward 
this goal over the past decade. First, the reference genome 
sequence is continuously being improved towards a near­
complete view of its content and structure. Second, the 
generation and use of mapping strains to locate genetic 
elements underlying the many rat disease models is still 
increasing and, finally, enor  mous progress has been made 
in the development of gene targeting techniques in this 
species. Clearly, these different gene­targeting techniques 
are  highly  complementary,  all  having  specific  features, 
advantages  and  disadvantages  (Table  2).  It  is  therefore 
unlikely that one technique will completely prevail over 
another.  It  is  more  likely  that  certain  aspects  of  the 
different techniques will be combined to strengthen the 
approach or facilitate a specific output. For example, ES 
cells  or  iPS  cells  can  be  used  to  specifically  target  a 
specific locus, or to generate a series of mutants in QTL 
regions, by incorporating a transposon by homologous 
recombi  nation, as has been done in mice [53], followed 
by  local  hopping,  insertion  of  a  transposon  near  its 
Table 2. Comparison of available rat mutagenesis techniques
  Targeted 
Technique  or random  Advantages  Disadvantages
ENU mutagenesis target-selected mutagenesis  Random  High mutation efficiency  Mutation discovery is relatively laborious
    Easily scalable  Background mutations
    Allows for allelic series 
Transposon-tagged mutagenesis  Random  Gene insertions easily detectable by   Relatively low mutation efficiency 
    reporter gene cassettes
    Integration site easy to identify  Biased genomic integration pattern
ZFN-mediated gene targeting  Targeted  Allows gene targeting by NHEJ and   Modular assembly of zinc-finger arrays is
    theoretically allows homologous   relatively unsuccessful 
    recombination
    High efficiency in introducing DSBs  Commercial ZFNs are expensive
Homologous recombination in ES or iPS cells  Targeted  Enables targeted knockouts, knock-ins   Homologous recombination has still not 
    and conditional alleles  been shown in rat ES and iPS cells
ENU, N-ethyl-N-nitrosourea; ES, embryonic stem; iPS, induced pluripotent stem; ZFN, zinc-finger nuclease; NHEJ, nonhomologous end joining; DSBs, double-strand 
breaks.
Box 2. Isolation of pluripotent rat ES cells
Until recently, the only targetable mammalian ES cells were derived from a few mouse inbred strains, mainly 129 [61], and the isolation 
and culture conditions were empirically based on these limited cell lines. However, the same conditions did not yield ES cells from other 
mouse strains or species. In 2008, a groundbreaking study reported that external cues were dispensable for propagation of ES cells in 
culture. Instead, the elimination of internal differentiation-inducing signals was sufficient for self-renewal [62]. By adding three inhibitors 
CHIR99021, PD184352 and SU5402 (3i) that prevent differentiation cues delivered through fibroblast growth factor (FGF)/ERK signaling or 
glycogen synthase kinase 3 (GSK3) activity, ES cells from other mouse strains [62] and also from rats [32,33] maintained pluripotency when 
propagated in vitro. So far, however, only one transgenic rat model developed using this technique has been reported [34].
There are several possible explanations for the current inefficiency in generating knockout rats by ES cell-based homologous 
recombination. First, genetic manipulation of rat ES cells in the 3i condition was reported to be technically challenging because of 
cell-adhesion deficiency and high drug-selection sensitivity [33]. Nevertheless, it was also postulated that culturing rat ES cells under 2i 
conditions, whereby the two inhibitors of fibroblast growth factor (FGF)/ERK signaling are replaced by one more potent MEK inhibitor 
[32,33], can overcome these problems. However, it still has to be determined whether rat ES cells retain pluripotency after long-term 
culture under these conditions. Moreover, even if these problems are overcome, it still has to be determined whether the efficiency of 
homologous recombination as applied in mouse ES cells is sufficient for gene targeting. It is known, for example, that the application of 
this technique in human ES cells is highly inefficient [63]. Second, the incidence of germline transmission is still low [32], which is also 
observed in mouse ES cells unless C57BL/6 strain blastocysts are used as hosts [64], underlining the need to systematically screen different 
donor and host strain combinations. Finally, although the karyotypes of the rat ES cells were found to be reasonably stable at earlier 
passages, chromosomal abnormalities increased at higher passages [32,33]. This finding can have consequences for generating knockout 
animals because chromosomal abnormality is one of the major causes of loss of germline competence of mouse ES cells [65]. Again, cells 
derived under 2i conditions did not display chromosomal abnormalities [34].
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in an objective manner. There are high expectations for 
gene targeting by homologous recombination in ES cells 
or  iPS  cells  (Box  2),  especially  for  the  generation  of 
conditional knockout alleles and knock­ins. Alternatively, 
the  emerging  technique  of  ZFN­mediated  mutagenesis 
could  also  enable  homologous  recombination  with 
exogenous  DNA,  without  the  need  for  ES  cell  mani­
pulation  and  time­consuming  selection  procedures,  by 
simply co­injecting the DNA construct for recom  bination 
together  with  the  mRNA  encoding  the  ZFNs  [26], 
although  a  proof­of­principle  for  this  remains  to  be 
demonstrated for the rat.
In  conclusion,  technical  developments  for 
manipulating  the  rat  genome  have  contributed  to 
expanding the genetic toolbox in this model organism. 
In the coming years, one can expect these technologies 
to  improve  in  efficiency  and  versatility  and  become 
routine  tools  in  rat  genetics.  The  use  of  rat  knockout 
models  is  expected  to  signifi  cantly  contribute  to 
biomedical  research  by  enabling  mammalian 
interspecies  phenotypic  comparisons  and  by  taking 
advantage of species­specific characteristics for studying 
different aspects of human physiology and disease.
Published: 29 September 2010
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